243 related articles for article (PubMed ID: 31292181)
1. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
[TBL] [Abstract][Full Text] [Related]
2. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
[TBL] [Abstract][Full Text] [Related]
3. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
[TBL] [Abstract][Full Text] [Related]
4. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
[TBL] [Abstract][Full Text] [Related]
5. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
[TBL] [Abstract][Full Text] [Related]
6. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
Michielsens CA; den Broeder N; van den Hoogen FH; Mahler EA; Teerenstra S; van der Heijde D; Verhoef LM; den Broeder AA
Ann Rheum Dis; 2022 Oct; 81(10):1392-1399. PubMed ID: 35701155
[TBL] [Abstract][Full Text] [Related]
7. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis.
Vinson D; Molet-Benhamou L; Degboé Y; den Broeder A; Ibrahim F; Pontes C; Westhovens R; Závada J; Pham T; Barnetche T; Constantin A; Ruyssen-Witrand A
Arthritis Res Ther; 2020 Apr; 22(1):97. PubMed ID: 32349791
[TBL] [Abstract][Full Text] [Related]
8. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
[TBL] [Abstract][Full Text] [Related]
9. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
[TBL] [Abstract][Full Text] [Related]
10. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
11. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.
Ye W; Tucker LJ; Coates LC
Drugs; 2018 Nov; 78(16):1705-1715. PubMed ID: 30341684
[TBL] [Abstract][Full Text] [Related]
12. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
[TBL] [Abstract][Full Text] [Related]
13. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
[TBL] [Abstract][Full Text] [Related]
14. To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question.
Lukasik Z; Carron P; Webers C
Best Pract Res Clin Rheumatol; 2023 Sep; 37(3):101869. PubMed ID: 37658017
[TBL] [Abstract][Full Text] [Related]
15. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.
Secher AEP; Granath F; Glintborg B; Rom A; Hetland ML; Hellgren K
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328400
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.
Chen MH; Lee MH; Liao HT; Chen WS; Lai CC; Tsai CY
Clin Rheumatol; 2018 Feb; 37(2):429-438. PubMed ID: 29307092
[TBL] [Abstract][Full Text] [Related]
17. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
18. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.
Valero M; Sánchez-Piedra C; Freire M; Colazo M; Busquets N; Meriño-Ibarra E; Rodríguez-Lozano C; Manrique S; Campos C; Sánchez-Alonso F; Castrejón I
Arthritis Res Ther; 2023 May; 25(1):86. PubMed ID: 37217997
[TBL] [Abstract][Full Text] [Related]
20. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
